Regeneron accused of ‘fraudulent’ drug-pricing reporting for eye drug Eylea

The Department of Justice on Wednesday accused drug maker Regeneron Pharmaceuticals Inc. of fraudulent practices related the pricing of its blockbuster vision-impairment drug Eylea, boosting its sales in the process.

Previous post Rent the Runway sees ‘milestone’ 2024 and breakeven cash flow, as stock soars
Next post Nvidia doesn’t have a monopoly in AI — though it sure seems that way